by Lupus Foundation, Ohio | Oct 2, 2026 | Lupus Foundation of America, News & Events
A Phase I study of the investigational CAR-T cell therapy prulacabtagene leucel (prula-cel) found that some people with SLE, including those with lupus nephritis (LN), achieved remission and kidney-related responses after a single treatment. This post was originally...
by Lupus Foundation, Ohio | Sep 30, 2026 | Lupus Foundation of America, News & Events
A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and more than half using two or more. This post was originally...
by Lupus Foundation, Ohio | Sep 29, 2026 | Lupus Foundation of America, News & Events
A new study found that people with systemic lupus erythematosus (SLE) who also had depression, anxiety and/or post-traumatic stress disorder (PTSD) experienced higher rates of emergency department visits and hospitalizations than those without these diagnoses. This...
by Lupus Foundation, Ohio | Sep 25, 2026 | Lupus Foundation of America, News & Events
Immunovant has announced topline results from a proof-of-concept study evaluating treatment imeroprubart (IMVT-1402) in people with cutaneous lupus erythematosus (CLE). This post was originally published on this...
by Lupus Foundation, Ohio | Sep 21, 2026 | Lupus Foundation of America, News & Events
A new systematic review and meta-analysis found that people with systemic lupus erythematosus (SLE) had a significantly higher risk of stroke compared with people without SLE. This post was originally published on this...
by Lupus Foundation, Ohio | Sep 18, 2026 | Lupus Foundation of America, News & Events
A new study found that non-Hispanic Black individuals with systemic lupus erythematosus (SLE) experienced the highest rates of maternal cardiovascular events, maternal adverse pregnancy outcomes and infant adverse outcomes. This post was originally published on this...
